Publications

Detailed Information

Cancer screening using (18)F-FDG PET/CT in Korean asymptomatic volunteers: a preliminary report

DC Field Value Language
dc.contributor.authorLee, Jeong Won-
dc.contributor.authorKang, Keon Wook-
dc.contributor.authorPaeng, Jin Chul-
dc.contributor.authorLee, Sang Mi-
dc.contributor.authorChung, June-Key-
dc.contributor.authorLee, Dong Soo-
dc.contributor.authorLee, Myung Chul-
dc.contributor.authorJang, Su Jin-
dc.date.accessioned2012-07-03T07:00:53Z-
dc.date.available2012-07-03T07:00:53Z-
dc.date.issued2009-09-
dc.identifier.citationANNALS OF NUCLEAR MEDICINE; Vol.23 7; 685-691ko_KR
dc.identifier.issn0914-7187-
dc.identifier.urihttps://hdl.handle.net/10371/78278-
dc.description.abstractThis study was performed to evaluate the clinical value of (18)F-fluorodeoxyglucose (FDG) positron-emission tomography (PET)/computed tomography (CT) for cancer screening in Korean asymptomatic people. Between February 2004 and December 2006, 1,587 asymptomatic individuals underwent FDG PET/CT as part of a cancer screening program with some other diagnostic tests at the healthcare center of our hospital. After excluding patients with a history of malignant tumor, 1,336 subjects were enrolled. All PET/CT images were visually analyzed. In subjects showing positive findings for PET/CT or other screening tests, further diagnostic tests and pathological confirmation were performed. Of the 1,336 subjects, malignant tumors were found in 16 participants (1.2%, thyroid cancer: 9, lung cancer: 2, stomach cancer: 2, and others: 4). There were 47 cases (3.6%) of positive PET/CT findings-11 cases were true positive (thyroid cancer: 8, lung cancer: 1, renal cancer: 1, and invasive thymoma), and 36 false positive, and five cases were false negative. The overall detection rate of PET/CT was 0.8%, and the sensitivity, specificity, positive-predictive value, and negative-predictive value of PET/CT were 68.8, 97.2, 23.4, and 99.6%, respectively. Fluorodeoxyglucose positron-emission tomography has the potential to detect various kinds of malignant tumors in cancer screening test, and the overall detection rate of PET/CT was 0.8%. FDG PET/CT can be a useful cancer screening modality with the selection of high-risk group and appropriate combination with other screening modalities.ko_KR
dc.language.isoenko_KR
dc.publisherSPRINGERko_KR
dc.subject(18)F-fluorodeoxyglucoseko_KR
dc.subjectPositron-emission tomographyko_KR
dc.subjectCancer screeningko_KR
dc.titleCancer screening using (18)F-FDG PET/CT in Korean asymptomatic volunteers: a preliminary reportko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor이정원-
dc.contributor.AlternativeAuthor강건욱-
dc.contributor.AlternativeAuthor팽진철-
dc.contributor.AlternativeAuthor이상미-
dc.contributor.AlternativeAuthor장수진-
dc.contributor.AlternativeAuthor정준기-
dc.contributor.AlternativeAuthor이명철-
dc.contributor.AlternativeAuthor이동수-
dc.identifier.doi10.1007/s12149-009-0291-z-
dc.citation.journaltitleANNALS OF NUCLEAR MEDICINE-
dc.description.citedreferenceTerauchi T, 2008, ANN NUCL MED, V22, P379, DOI 10.1007/s12149-008-0130-7-
dc.description.citedreferenceKO D, 2008, NUCL MED MOL IMAGING, V42, P444-
dc.description.citedreferenceMinamimoto R, 2007, ANN NUCL MED, V21, P481, DOI 10.1007/s12149-007-0061-8-
dc.description.citedreferenceCook GJR, 2007, Q J NUCL MED MOL IM, V51, P235-
dc.description.citedreferenceKojima S, 2007, EUR J CANCER, V43, P1842, DOI 10.1016/j.ejca.2007.05.010-
dc.description.citedreferenceGhotbi N, 2007, ASIAN PAC J CANCER P, V8, P93-
dc.description.citedreferenceOno K, 2007, ANN NUCL MED, V21, P65-
dc.description.citedreferenceBrix G, 2005, J NUCL MED, V46, P608-
dc.description.citedreferenceWeckesser M, 2005, EUR J NUCL MED MOL I, V32, P342, DOI 10.1007/s00259-005-1775-2-
dc.description.citedreferenceChen YK, 2004, ANTICANCER RES, V24, P4103-
dc.description.citedreferenceRohren EM, 2004, RADIOLOGY, V231, P305, DOI 10.1148/radiol.2312021185-
dc.description.citedreferenceBar-Shalom R, 2003, J NUCL MED, V44, P1200-
dc.description.citedreferenceStahl A, 2003, EUR J NUCL MED MOL I, V30, P288, DOI 10.1007/s00259-002-1029-5-
dc.description.citedreferenceShen YY, 2003, NEOPLASMA, V50, P217-
dc.description.citedreferenceBarratt A, 2002, J EPIDEMIOL COMMUN H, V56, P899-
dc.description.citedreferenceYasuda S, 2000, BRIT J CANCER, V83, P1607, DOI 10.1054/bjoc.2000.1496-
dc.description.citedreferenceCharron M, 2000, CLIN NUCL MED, V25, P905-
dc.description.citedreferenceHigashi K, 1998, J NUCL MED, V39, P1016-
dc.description.citedreferenceDeloar HM, 1998, EUR J NUCL MED, V25, P565-
dc.description.citedreference*ICRP, 1991, ICRP PUBL, V60-
dc.description.citedreference*WHO, WHO FACT SHEETS-
dc.description.tc4-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share